Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)

Hisashi Hidaka, Namiki Izumi, Takeshi Aramaki, Masafumi Ikeda, Yoshitaka Inaba, Kazuho Imanaka, Takuji Okusaka, Susumu Kanazawa, Shuichi Kaneko, Shinichi Kora, Hiroya Saito, Junji Furuse, Osamu Matsui, Tatsuya Yamashita, Osamu Yokosuka, Satoshi Morita, Hitoshi Arioka, Masatoshi Kudo, Yasuaki Arai

Research output: Contribution to journalArticle

Abstract

A randomized, phase III trial of orantinib in combination with transcatheter arterial chemoembolization (TACE) did not prolong overall survival (OS) over placebo (ORIENTAL study). A subgroup analysis was conducted to evaluate the efficacy and safety of orantinib in Japanese patients enrolled in the ORIENTAL study. The data of Japanese patients from this study were analyzed. The overall survival (OS), time to progression (TTP), and time to TACE failure (TTTF) were compared between orantinib and placebo arms using stratified log-rank test. Since TTTF in patients with Barcelona Clinic Liver Cancer stage B (BCLC-B) showed favor outcome in this study, the OS and TTTF according to BCLC staging system were also analyzed. The subgroup analysis consisted of 219 and 213 patients in the orantinib and placebo arms. Median OS was 32.5 vs 33.0 months (p = 0.906), median TTP was 4.7 vs 3.1 months (p = 0.011), and median TTTF was 25.3 vs 18.2 months (p = 0.160) in the orantinib and placebo groups, respectively. Patients with BCLC-B in the orantinib and placebo groups showed a median OS of 33.7 and 30.1 months, respectively (p = 0.260), while the corresponding median TTTF were 25.3 and 14.0 months (p = 0.125). The Japanese population safety profile was similar to all over population in the ORIENTAL study. No significant differences were observed in the OS and TTTF though the TTP was significantly improved in the orantinib arm. The OS and TTTF showed a tendency to be prolonged following orantinib treatment of Japanese HCC patients with BCLC-B in the ORIENTAL study.

Original languageEnglish
Article number52
JournalMedical Oncology
Volume36
Issue number6
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Safety
Survival
Placebos
Liver Neoplasms
orantinib
Population
Outcome Assessment (Health Care)

Keywords

  • Angiogenic factors
  • Molecular targeted agents
  • Platelet-derived growth factor
  • Unresectable HCC
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). / Hidaka, Hisashi; Izumi, Namiki; Aramaki, Takeshi; Ikeda, Masafumi; Inaba, Yoshitaka; Imanaka, Kazuho; Okusaka, Takuji; Kanazawa, Susumu; Kaneko, Shuichi; Kora, Shinichi; Saito, Hiroya; Furuse, Junji; Matsui, Osamu; Yamashita, Tatsuya; Yokosuka, Osamu; Morita, Satoshi; Arioka, Hitoshi; Kudo, Masatoshi; Arai, Yasuaki.

In: Medical Oncology, Vol. 36, No. 6, 52, 01.06.2019.

Research output: Contribution to journalArticle

Hidaka, H, Izumi, N, Aramaki, T, Ikeda, M, Inaba, Y, Imanaka, K, Okusaka, T, Kanazawa, S, Kaneko, S, Kora, S, Saito, H, Furuse, J, Matsui, O, Yamashita, T, Yokosuka, O, Morita, S, Arioka, H, Kudo, M & Arai, Y 2019, 'Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)', Medical Oncology, vol. 36, no. 6, 52. https://doi.org/10.1007/s12032-019-1272-2
Hidaka, Hisashi ; Izumi, Namiki ; Aramaki, Takeshi ; Ikeda, Masafumi ; Inaba, Yoshitaka ; Imanaka, Kazuho ; Okusaka, Takuji ; Kanazawa, Susumu ; Kaneko, Shuichi ; Kora, Shinichi ; Saito, Hiroya ; Furuse, Junji ; Matsui, Osamu ; Yamashita, Tatsuya ; Yokosuka, Osamu ; Morita, Satoshi ; Arioka, Hitoshi ; Kudo, Masatoshi ; Arai, Yasuaki. / Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). In: Medical Oncology. 2019 ; Vol. 36, No. 6.
@article{6f09fe1000444a479d1979a85cc4c138,
title = "Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)",
abstract = "A randomized, phase III trial of orantinib in combination with transcatheter arterial chemoembolization (TACE) did not prolong overall survival (OS) over placebo (ORIENTAL study). A subgroup analysis was conducted to evaluate the efficacy and safety of orantinib in Japanese patients enrolled in the ORIENTAL study. The data of Japanese patients from this study were analyzed. The overall survival (OS), time to progression (TTP), and time to TACE failure (TTTF) were compared between orantinib and placebo arms using stratified log-rank test. Since TTTF in patients with Barcelona Clinic Liver Cancer stage B (BCLC-B) showed favor outcome in this study, the OS and TTTF according to BCLC staging system were also analyzed. The subgroup analysis consisted of 219 and 213 patients in the orantinib and placebo arms. Median OS was 32.5 vs 33.0 months (p = 0.906), median TTP was 4.7 vs 3.1 months (p = 0.011), and median TTTF was 25.3 vs 18.2 months (p = 0.160) in the orantinib and placebo groups, respectively. Patients with BCLC-B in the orantinib and placebo groups showed a median OS of 33.7 and 30.1 months, respectively (p = 0.260), while the corresponding median TTTF were 25.3 and 14.0 months (p = 0.125). The Japanese population safety profile was similar to all over population in the ORIENTAL study. No significant differences were observed in the OS and TTTF though the TTP was significantly improved in the orantinib arm. The OS and TTTF showed a tendency to be prolonged following orantinib treatment of Japanese HCC patients with BCLC-B in the ORIENTAL study.",
keywords = "Angiogenic factors, Molecular targeted agents, Platelet-derived growth factor, Unresectable HCC, Vascular endothelial growth factor",
author = "Hisashi Hidaka and Namiki Izumi and Takeshi Aramaki and Masafumi Ikeda and Yoshitaka Inaba and Kazuho Imanaka and Takuji Okusaka and Susumu Kanazawa and Shuichi Kaneko and Shinichi Kora and Hiroya Saito and Junji Furuse and Osamu Matsui and Tatsuya Yamashita and Osamu Yokosuka and Satoshi Morita and Hitoshi Arioka and Masatoshi Kudo and Yasuaki Arai",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s12032-019-1272-2",
language = "English",
volume = "36",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "6",

}

TY - JOUR

T1 - Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)

AU - Hidaka, Hisashi

AU - Izumi, Namiki

AU - Aramaki, Takeshi

AU - Ikeda, Masafumi

AU - Inaba, Yoshitaka

AU - Imanaka, Kazuho

AU - Okusaka, Takuji

AU - Kanazawa, Susumu

AU - Kaneko, Shuichi

AU - Kora, Shinichi

AU - Saito, Hiroya

AU - Furuse, Junji

AU - Matsui, Osamu

AU - Yamashita, Tatsuya

AU - Yokosuka, Osamu

AU - Morita, Satoshi

AU - Arioka, Hitoshi

AU - Kudo, Masatoshi

AU - Arai, Yasuaki

PY - 2019/6/1

Y1 - 2019/6/1

N2 - A randomized, phase III trial of orantinib in combination with transcatheter arterial chemoembolization (TACE) did not prolong overall survival (OS) over placebo (ORIENTAL study). A subgroup analysis was conducted to evaluate the efficacy and safety of orantinib in Japanese patients enrolled in the ORIENTAL study. The data of Japanese patients from this study were analyzed. The overall survival (OS), time to progression (TTP), and time to TACE failure (TTTF) were compared between orantinib and placebo arms using stratified log-rank test. Since TTTF in patients with Barcelona Clinic Liver Cancer stage B (BCLC-B) showed favor outcome in this study, the OS and TTTF according to BCLC staging system were also analyzed. The subgroup analysis consisted of 219 and 213 patients in the orantinib and placebo arms. Median OS was 32.5 vs 33.0 months (p = 0.906), median TTP was 4.7 vs 3.1 months (p = 0.011), and median TTTF was 25.3 vs 18.2 months (p = 0.160) in the orantinib and placebo groups, respectively. Patients with BCLC-B in the orantinib and placebo groups showed a median OS of 33.7 and 30.1 months, respectively (p = 0.260), while the corresponding median TTTF were 25.3 and 14.0 months (p = 0.125). The Japanese population safety profile was similar to all over population in the ORIENTAL study. No significant differences were observed in the OS and TTTF though the TTP was significantly improved in the orantinib arm. The OS and TTTF showed a tendency to be prolonged following orantinib treatment of Japanese HCC patients with BCLC-B in the ORIENTAL study.

AB - A randomized, phase III trial of orantinib in combination with transcatheter arterial chemoembolization (TACE) did not prolong overall survival (OS) over placebo (ORIENTAL study). A subgroup analysis was conducted to evaluate the efficacy and safety of orantinib in Japanese patients enrolled in the ORIENTAL study. The data of Japanese patients from this study were analyzed. The overall survival (OS), time to progression (TTP), and time to TACE failure (TTTF) were compared between orantinib and placebo arms using stratified log-rank test. Since TTTF in patients with Barcelona Clinic Liver Cancer stage B (BCLC-B) showed favor outcome in this study, the OS and TTTF according to BCLC staging system were also analyzed. The subgroup analysis consisted of 219 and 213 patients in the orantinib and placebo arms. Median OS was 32.5 vs 33.0 months (p = 0.906), median TTP was 4.7 vs 3.1 months (p = 0.011), and median TTTF was 25.3 vs 18.2 months (p = 0.160) in the orantinib and placebo groups, respectively. Patients with BCLC-B in the orantinib and placebo groups showed a median OS of 33.7 and 30.1 months, respectively (p = 0.260), while the corresponding median TTTF were 25.3 and 14.0 months (p = 0.125). The Japanese population safety profile was similar to all over population in the ORIENTAL study. No significant differences were observed in the OS and TTTF though the TTP was significantly improved in the orantinib arm. The OS and TTTF showed a tendency to be prolonged following orantinib treatment of Japanese HCC patients with BCLC-B in the ORIENTAL study.

KW - Angiogenic factors

KW - Molecular targeted agents

KW - Platelet-derived growth factor

KW - Unresectable HCC

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85065236740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065236740&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1272-2

DO - 10.1007/s12032-019-1272-2

M3 - Article

VL - 36

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 6

M1 - 52

ER -